NVCT
Nuvectis Pharma Inc
NASDAQ: NVCT · HEALTHCARE · BIOTECHNOLOGY
$10.00
+2.99% today
Updated 2026-05-06
Market cap
$268.66M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.31
Dividend yield
—
52W range
$6 – $11
Volume
0.1M
Nuvectis Pharma Inc (NVCT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $149000.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | -100.0% | — | — |
| Cost of revenue | — | $12.89M | $19.23M | $22.90M | — | — |
| Gross profit | — | $-12.89M | $-19.09M | $-22.90M | — | — |
| Gross margin | — | — | -12808.7% | — | — | — |
| R&D | — | $9.54M | $13.23M | $15.38M | $12.92M | $18.15M |
| SG&A | $24000.00 | $3.35M | $6.01M | $7.52M | $6.93M | $9.42M |
| Operating income | $-10000.00 | $-12.89M | $-19.23M | $-22.90M | $-19.85M | $-27.57M |
| Operating margin | — | — | -12908.7% | — | — | — |
| EBITDA | $-10000.00 | $-12.89M | $-18.94M | $-22.90M | $-19.00M | $-27.57M |
| EBITDA margin | — | — | -12708.7% | — | — | — |
| EBIT | $-34000.00 | $-12.89M | $-19.23M | $-21.90M | $-19.85M | — |
| Interest expense | $0.00 | $4000.00 | $149000.00 | — | — | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10000.00 | $-12.89M | $-18.79M | $-22.26M | $-19.00M | $-26.44M |
| Net income growth (YoY) | — | -128760.0% | -45.8% | -18.5% | +14.6% | -39.2% |
| Profit margin | — | — | -12608.7% | — | — | — |